MedCap AB (publ) - Deep Dive Research Report

Ticker: MCAP.ST (Nasdaq Stockholm) | Sector: Healthcare / Life Science | Report date: 24 July 2026

A note on sourcing before we begin. MedCap is a Swedish small-cap that does not host US-style earnings calls with published transcripts. Instead, each quarter it releases a detailed interim report carrying an extensive signed CEO letter, and it holds an annual general meeting presentation. Those interim reports and their management commentary are the functional equivalent of a concall for a company of this size, and this report treats the last six of them (Q1 2025 through Q2 2026) as the six "concalls." The most recent, the January-June 2026 half-year report, was released on 21 July 2026, three days before this report, and is fully captured below.

Section 1: What the company does

MedCap buys and owns small, profitable healthcare companies in the Nordic region and then holds them for a very long time. It is not a fund, and it is not a trading house. It is a permanent-capital owner, closer in spirit to a miniature Nordic version of a serial-acquirer compounder (think of the Lifco or Indutrade model) but pointed entirely at life science. It owns roughly a dozen operating subsidiaries outright, groups them into three business areas, lets them run semi-autonomously under their own management, and reinvests the group's cash flow into buying more of them.

The businesses it owns are deliberately unglamorous and niche. One makes communication aids for people with autism or cognitive disabilities. One makes orthopaedic shoes and prosthetic components. One makes ECG machines. One is a Nordic specialty-pharma company that licenses and distributes small, hard-to-source medicines for children and rare conditions, and also runs a contract drug-manufacturing plant. None of these are billion-krona markets on their own. That is the entire point. MedCap hunts for market-leading positions in markets too small for large-cap medtech and pharma to bother with, where a well-run niche leader can earn high margins and defend its position for decades.

The founding story explains the discipline. MedCap listed in the mid-2000s as a life-science investment vehicle and spent its early years as a messier, more venture-flavoured holding company. Karl Tobieson took over as CEO in 2008 and spent the following decade turning it into a focused operational owner of cash-generative subsidiaries rather than a portfolio of speculative bets. He handed the CEO role to Anders Dahlberg in November 2020 and moved to chairman of the board, where he remains a large shareholder. The Tobieson-to-Dahlberg handover preserved the model: acquire niche healthcare leaders, improve them operationally, hold them, compound.

The core value proposition to a seller is that MedCap is a stable, long-term home. A Nordic founder of a small orthopaedics or specialty-pharma business who wants to retire, or de-risk, but does not want their company flipped by a private-equity fund in four years, can sell to MedCap and keep running it. MedCap frequently buys 85% and leaves the founder-CEO with 15% (as it did with Danrehab), aligning incentives and keeping the operator engaged. To the group's shareholders, the value proposition is a diversified, self-funding portfolio of defensive healthcare cash flows that grows both organically and by bolt-on acquisition, financed from its own balance sheet with very little debt.

MedCap describes itself as "an active, long-term owner" that places "great emphasis on the subsidiaries' operational business plans" rather than short-term financial engineering. That sentence is the whole strategy: own good niche healthcare businesses, help them operationally, never feel forced to sell.

A concrete example of the model in action: in 2025 MedCap's assistive-tech subsidiary Abilia acquired 85% of Danrehab, a Danish maker of hygiene chairs and bed aids with around DKK 42m of sales and good profitability. Abilia already sold cognition and communication aids into the same Nordic municipal and healthcare-procurement channels. Danrehab plugs into that channel, gains MedCap's balance sheet and purchasing scale, keeps its CEO on with a 15% stake, and MedCap gains another profitable niche product line sold to the same buyers. That is the flywheel repeated dozens of times.

Section 2: Business segments

MedCap reports three business areas. In the 2025 sales mix they split roughly Assistive Tech 42%, MedTech 34%, Specialty Pharma 24%.

Assistive Tech (~42% of sales) - the cash cow and the steadiest grower

This is the largest and most reliable business area. It groups the operating companies Abilia, Erimed, Trident, Huka, Danrehab, Swedelift (and the recently acquired Dutch LivAssured). What ties them together is that they all sell products that help people with disabilities, mobility limitations, or cognitive impairments live more independently, and they all sell into the same Nordic buyers: municipalities, regional healthcare authorities, and public-procurement assistive-aid budgets.

Abilia is the anchor. It develops and markets aids for communication, cognition, and environmental control (for example, tools and software that help autistic or cognitively impaired users structure their day, communicate, or control their home environment). Erimed is a Nordic supplier of orthopaedic footwear, hard and soft orthotics, prosthetics and prosthetic components, and its own Dictus Band (a foot-drop aid). Huka makes special-needs cycles and mobility products. Trident and Swedelift supply mobility and lifting aids. Danrehab adds hygiene chairs and bed aids. LivAssured, bought in October 2025, brings Nightwatch, a wearable medical device that detects epileptic seizures at night and alerts carers.

The core capability here is not manufacturing wizardry; it is the distribution relationship with public healthcare buyers and the accumulated position on procurement framework agreements. Getting a product onto a Swedish region's or a Danish municipality's approved assistive-aid list takes years, references, and reliability. Once there, reorders are sticky. This business area is the group's steady compounder: management repeatedly reported strong Assistive Tech performance (EBITA up around 35% in Q1 2025), and it is where most of the bolt-on acquisitions land because the channel absorbs new product lines easily. Its competitors are large orthopaedics and mobility players (Ottobock, Össur) and specialist AAC firms (Tobii Dynavox), but Abilia and Erimed win on Nordic-specific product fit, local service, and entrenched procurement positions rather than scale.

MedTech (~34% of sales) - the growth and margin engine

MedTech groups Cardiolex, Inpac, Multi-ply, Toul Meditech and, from mid-2026, Biopsafe. These are genuine device and consumable manufacturers with their own technology and, crucially, their own export markets beyond the Nordics.

Cardiolex develops, manufactures, and sells complete ECG (electrocardiogram) systems, hardware plus software, positioned on simplicity and efficient clinical workflow. Toul Meditech makes mobile ultra-clean-air units that create a sterile zone over an operating field or wound-care setting, sold internationally. Inpac and Multi-ply are packaging and materials businesses serving life-science and medical customers. Biopsafe, acquired for around DKK 115m and closed in June 2026, makes closed, pre-filled biopsy sample containers (a formalin-filled container that a surgeon drops a tissue sample straight into, reducing staff exposure to formaldehyde). It is a classic MedCap target: a single defensible consumable product, profitable, with room to expand geographically.

The core capability in MedTech is regulatory-certified device manufacturing (CE marking under the EU Medical Device Regulation, quality-management systems, clinical validation) plus, for consumables like Biopsafe's containers, a razor-and-blade recurring revenue profile. This is the business area with the most international reach and the strongest margin trajectory. Management has consistently pointed to MedTech (alongside Assistive Tech) as delivering good organic growth, and the segment's blend of proprietary devices and recurring consumables is why it carries the group's expanding margin story.

Specialty Pharma (~24% of sales) - the volatile, higher-risk-higher-reward leg

This business area is essentially Unimedic, split into three parts: Unimedic Pharma (specialty/licensed medicines), an unlicensed-medicines import business, and Unimedic AB, a contract development and manufacturing organisation (CDMO) that makes pharmaceuticals both for the group's own Pharma arm and for external customers. The recent Danish bolt-on XGX Pharma (bought by Unimedic Pharma for DKK 135m upfront plus up to DKK 140m earn-out) sits here too, bringing seven marketed niche products and a pipeline of around 20 products in late-stage development or registration.

Unimedic's business is sourcing, licensing, and supplying small-volume specialist medicines - drugs for children, rare conditions, and unlicensed imports where no large pharma company finds it worthwhile to operate. Its geographic market is Northern Europe. The core capability is regulatory and licensing know-how: the ability to register, license, and distribute niche medicines, and to negotiate the in-licensing and partnership deals that fill the portfolio. XGX's 20-product pipeline is the growth option.

This is the most volatile leg, and 2025 proved it. Specialty Pharma's result dropped more than 50% because of a UK market change: royalties on a melatonin product paid into the UK collapsed (roughly SEK 10.7m of high-margin royalty income that was around SEK 5.9m in a single 2024 quarter essentially disappeared after a regulatory/market shift in the UK). Separately, the CDMO (Unimedic AB) saw demand for certain contract-manufactured products fall, weakening its outlook and requiring "improvement measures." So within Specialty Pharma there are really two different risk profiles: a high-margin but concentration-prone licensing/royalty business, and a lower-margin contract-manufacturing business exposed to a handful of external customers' volumes. Management's stated fix is to broaden the portfolio through more licensing, partnerships, and acquisitions (hence XGX) and to lift CDMO efficiency, with margins guided to improve in the second half of 2026 and beyond.

Section 3: Products and business detail

MedCap's "product" at the group level is capital allocation, but the underlying catalogue across the operating companies is concrete and worth naming.

In Assistive Tech: Abilia's communication and cognition aids and control software; Erimed's orthopaedic shoes, hard and soft orthotics, prosthetics and prosthetic components, and the in-house Dictus Band for foot drop; Huka's adapted cycles and mobility products; Danrehab's hygiene chairs and bed aids; Swedelift's and Trident's lifting and mobility aids; and LivAssured's Nightwatch nocturnal epileptic-seizure detector. These are sold overwhelmingly as physical aids reimbursed or procured through public healthcare systems, with a service and reorder tail.

In MedTech: Cardiolex's complete ECG solution (resting ECG hardware, acquisition software, and management software) built around clinical simplicity and workflow; Toul Meditech's mobile laminar-airflow / ultra-clean-air units that create a sterile field for surgery and wound care; Inpac's and Multi-ply's medical and life-science packaging and materials; and Biopsafe's closed, formalin-pre-filled biopsy containers, a consumable bought repeatedly by pathology and surgical departments and valued because the tissue sample never exposes staff to open formaldehyde.

In Specialty Pharma: Unimedic Pharma's portfolio of licensed specialist medicines (paediatric and niche indications), its unlicensed-import medicine supply, XGX Pharma's seven marketed niche products plus its ~20-product late-stage/registration pipeline, and Unimedic AB's CDMO service manufacturing pharmaceuticals for both internal and external customers.

The manufacturing and regulatory reality differs sharply by area. The MedTech devices require CE marking under the EU Medical Device Regulation and ISO-quality-managed production; the Specialty Pharma CDMO requires GMP-certified pharmaceutical manufacturing and holds the regulatory licences to make and release drugs; the Assistive Tech products are lighter on manufacturing complexity but heavy on procurement qualification. Products are made across Sweden and Denmark primarily, with the group's centre of gravity in Sweden.

Geographically, the group is Nordic-centred: roughly Sweden 50%, rest of Nordic 25%, rest of Europe 21%, rest of world 4% (as reported around Q1 2025). MedTech's devices (Toul Meditech's clean-air units, Cardiolex's ECG) reach furthest internationally; Assistive Tech and Specialty Pharma are more tightly Nordic/Northern-European. Notable recent milestones are almost all acquisitions rather than plant builds: Danrehab (Jan 2025), XGX Pharma (signed 2025, closed Q3 2025), LivAssured/Nightwatch (Oct 2025), and Biopsafe (closed June 2026). The pattern is bolt-on M&A into existing channels rather than greenfield capacity.

Section 4: Customers

MedCap has three distinct customer worlds, one per business area, and they behave very differently.

For Assistive Tech, the buyer is the public sector. Purchasing decisions are made by Nordic municipalities, regional health authorities, and their procurement officers who assemble approved-aid framework agreements. The people making the decision are occupational therapists, procurement specialists, and clinical assessors, and the criteria are product suitability for a specific disability, reliability, service and support, and framework-agreement compliance rather than lowest price. Sales cycles are long because getting onto a framework agreement is a formal, periodic tender process. The switching cost is structural: once a product is specified into a municipality's approved list and clinicians are trained on it, it stays until the next tender cycle, and the incumbent has references and installed-base familiarity. This is stable, defensive, reorder-driven revenue.

For MedTech, customers are hospitals, clinics, pathology labs, and surgical departments, increasingly outside the Nordics. The decision-makers are clinical department heads, biomedical engineering, and hospital procurement. They buy Cardiolex ECGs on workflow and total cost, Toul Meditech clean-air units on infection-control performance, and Biopsafe containers on staff-safety and regulatory compliance. Switching costs are highest for the consumables (Biopsafe containers, once designed into a pathology workflow, are reordered continuously) and for validated devices where re-qualifying a competitor is disruptive. Contract structure is a mix of capital-equipment sales with a consumable/service tail.

For Specialty Pharma, customers are healthcare systems, pharmacies, hospitals, and distribution partners across Northern Europe buying niche and unlicensed medicines, plus, on the CDMO side, external pharma companies contracting Unimedic to manufacture their products. The licensing/royalty business can be highly concentrated - the UK melatonin royalty collapse showed how a single product in a single market can swing the segment's result by more than half - and the CDMO's revenue depends on a limited set of external customers' order volumes, which management flagged as declining for certain products. This is the least predictable customer base in the group and the reason management is deliberately broadening the licensing portfolio (XGX) to reduce single-product dependence.

Overall the group has low customer concentration at the consolidated level (dozens of products across three unrelated buyer types) but meaningful concentration inside the Specialty Pharma leg specifically.

Section 5: Competitive landscape

MedCap does not compete as a single entity; each subsidiary competes in its own niche, which is itself part of the moat - no single competitor attacks the whole group.

In Assistive Tech, Abilia's communication and cognition aids compete with specialist AAC firms, most visibly Tobii Dynavox (the Swedish-listed AAC and eye-tracking leader), though the relationship is partly channel-based (Abilia resells some Tobii products in certain markets) and partly competitive in cognition/environmental-control aids. Erimed's orthopaedics and prosthetics compete against the global heavyweights Ottobock (German, private) and Össur (Icelandic, listed in Copenhagen). MedCap wins here not on scale - it cannot outspend Ottobock on R&D - but on Nordic-specific product fit, local service, and entrenched positions on regional procurement frameworks. It loses where a tender rewards global scale, breadth, or price.

In MedTech, Cardiolex competes in ECG against large diagnostics vendors (GE HealthCare, Philips) at the high end and numerous mid-tier ECG makers, winning on simplicity and workflow in smaller clinical settings rather than on installed-base breadth. Toul Meditech competes in surgical clean-air against larger operating-room-infrastructure players. Biopsafe competes with other pre-filled/closed specimen-container makers on safety compliance and price. These are fragmented niche markets where a focused specialist can hold a strong local or product-specific position.

In Specialty Pharma, Unimedic competes with other Nordic specialty and unlicensed-medicine suppliers and, on the CDMO side, with the broad universe of contract manufacturers. This is the least defensible leg: niche-medicine licensing positions can be undercut when a molecule's market economics shift (as the UK melatonin case showed), and CDMO capacity is a competitive, volume-sensitive business.

The real barrier to entry is not any single technology; it is the aggregate of dozens of small, defended niche positions, the regulatory certifications (MDR, GMP) each business holds, and the entrenched procurement and licensing relationships. A new entrant cannot replicate MedCap by launching one product; it would have to win dozens of separate niche battles. That said, this is not a wide-moat monopoly story. Margins are good but not extraordinary, competition in each niche is real, and the group's edge is disciplined ownership and channel entrenchment rather than irreplaceable technology.

(Peer market caps are approximate size references only and move constantly.)

Section 6: Industry

MedCap sits inside three overlapping healthcare sub-industries, all sharing one dominant demand driver: ageing Northern-European populations and publicly funded healthcare.

Demand for Assistive Tech is driven by demographics and disability policy. As Nordic populations age and as disability-inclusion and independent-living policy expands, public budgets for communication, mobility, and cognition aids grow structurally. This demand is remarkably non-cyclical because it is funded by municipal and regional health budgets rather than discretionary consumer or corporate spending. The regulatory environment (procurement rules, reimbursement, and MDR for devices) is a barrier that protects incumbents.

Demand for MedTech tracks hospital capital and consumable budgets, diagnostic volumes (ECGs performed), surgical volumes (clean-air units), and pathology throughput (biopsy containers). It is mildly cyclical on the capital-equipment side (hospitals can defer purchases) but the consumable and diagnostic-volume components are defensive. The whole area is shaped by the EU Medical Device Regulation, whose stringent (and expensive) certification requirements have squeezed marginal players and favoured established, compliant manufacturers - a tailwind for a disciplined owner like MedCap.

Demand for Specialty Pharma is driven by the persistent need for small-volume niche and paediatric medicines that big pharma neglects, and by outsourced pharmaceutical manufacturing. The specialty and unlicensed-medicine niche is defensive in aggregate but exposed to single-market regulatory shifts (the UK melatonin episode) and to reference-pricing and reimbursement policy. The CDMO end is more cyclical and volume-sensitive. For scale reference, adjacent markets such as pharmaceutical-grade melatonin and sodium oxybate are each in the low-single-digit-billion-USD range globally and growing mid-single-digit to high-single-digit percent annually, but MedCap participates only in narrow slices of these.

Across all three, the industry-level tailwinds are ageing demographics, rising healthcare spend, and MDR-driven consolidation favouring compliant incumbents. The headwinds are public-budget pressure and reference pricing (which can squeeze reimbursed products), regulatory change risk in individual national markets, and the ever-present competitive intensity of fragmented niche markets. MedCap's position in the supply chain is that of a Nordic niche manufacturer/distributor sitting between global component suppliers and local public healthcare buyers.

Section 7: Growth triggers

Drawn only from the six interim-report CEO commentaries (Q1 2025 through Q2 2026):

• Specialty Pharma margin recovery in H2 2026 and beyond. Management explicitly guided that the Specialty Pharma margin is expected to improve in the second half of 2026 as the UK-melatonin and CDMO headwinds annualise out and the broadened portfolio contributes. (Q1 2026 report, Apr 2026; repeated in the Q2 2026 report, 21 Jul 2026.)

• XGX Pharma integration and its ~20-product pipeline. XGX (closed Q3 2025) brought seven marketed products and around 20 niche products in late-stage development or registration; management expects it to boost Specialty Pharma growth and margins as those products launch. (Repeated across Q3 2025, Q4/FY 2025, and Q2 2026 reports.)

  Management framed XGX as "a fast-growing specialty pharma company with a pipeline of new products," with an earn-out of up to DKK 140m tied to 2025-2026 gross-profit growth - a structure that only pays out if the pipeline delivers.

• Biopsafe contribution in MedTech. The Biopsafe acquisition (closed 26 June 2026) adds a recurring-consumable biopsy-container product expected to support MedTech growth and margins from H2 2026. (Q2 2026 report, 21 Jul 2026.)

• LivAssured / Nightwatch commercialisation. The Dutch nocturnal-epileptic-seizure detector (acquired Oct 2025, ~EUR 4m sales) gives Assistive Tech a scalable medical-device product to push through Abilia's channel. (Q4/FY 2025 report, Jan 2026.)

• Continued bolt-on M&A funded by a near-unlevered balance sheet. Management repeatedly stated the ambition to keep acquiring, pointing to net debt/EBITDA of about 0.2x (ex-IFRS 16) as dry powder. (Q1 2026 report, Apr 2026.)

  The Q1 2026 commentary tied the strategy to capacity: a strong balance sheet at ~0.2x leverage explicitly kept "for further acquisitions."

• Continued organic growth in Assistive Tech and MedTech. Both areas were flagged as delivering good organic growth throughout the period, with Danrehab and other bolt-ons adding to it. (Repeated Q1 2025 through Q2 2026.)

Section 8: Key risks

Specialty Pharma single-product / single-market concentration. The clearest, already-realised risk. A single melatonin royalty stream into the UK swung the entire Specialty Pharma result by more than 50% when the UK market changed - roughly SEK 10.7m of high-margin royalty income (about SEK 5.9m in one 2024 quarter) that "virtually disappeared." The mechanism is that niche-medicine licensing income is inherently concentrated: one molecule, one market, one regulatory or reimbursement decision can erase a segment's profit. This is a high-probability, moderate-to-severe drag that has already happened once and could recur with another product. Management's XGX-led portfolio-broadening is the direct mitigation.

CDMO customer-volume dependence. Unimedic AB's contract-manufacturing arm depends on a limited set of external customers' order volumes, and management disclosed that demand for certain contract-manufactured products declined significantly, signalling a weaker CDMO year. If a large external customer reduces or pulls volume, fixed manufacturing costs bite and margins compress. Moderate probability, moderate impact, and management has flagged "ongoing improvement measures."

Acquisition execution and earn-out risk. The entire equity story depends on buying niche businesses at sensible prices and integrating them. The XGX deal carries an earn-out of up to DKK 140m tied to 2025-2026 gross-profit growth; overpaying, integration slippage, or a bolt-on that disappoints would break the compounding narrative. As the group grows, it must deploy more capital each year to move the needle, raising the bar on deal quality. Continuous, moderate risk inherent to any serial acquirer.

Public-budget and reimbursement pressure. Roughly three-quarters of sales are Nordic, much of it ultimately funded by municipal and regional health budgets and public reimbursement. Austerity, reference pricing, or procurement re-tendering that favours a cheaper competitor could pressure both volume and price in Assistive Tech and Specialty Pharma. High probability of gradual pressure, low probability of a sharp shock.

Regulatory / MDR cost burden. The MedTech devices must maintain MDR certification and the CDMO must maintain GMP compliance; tightening rules raise cost and can strand a marginal product line. This cuts both ways (it also consolidates the industry in favour of compliant incumbents like MedCap) but it is a real ongoing cost and execution risk.

Key-person and governance concentration. Chairman Karl Tobieson (the architect of the modern MedCap) and a small management team drive capital allocation; the founder/family and board hold significant stakes. The model's success is tied to continued disciplined stewardship, and the late-2025 insider selling by the chairman (see Section 11) is a data point worth watching, though not by itself alarming.

Section 9: Walk the talk

The six reporting periods used, most recent first: Q2 2026 (21 Jul 2026), Q1 2026 (Apr 2026), Q4/FY 2025 (Jan 2026), Q3 2025 (Oct 2025), Q2 2025 (Jul 2025), Q1 2025 (Apr 2025). The most recent is three days before this report.

The story that emerges across these six is of a management team that is candid about problems, does not dress up weak quarters, and delivers on its operational and acquisition commitments while being appropriately cautious on the one leg (Specialty Pharma) it could not fully control.

Start with Q1 2025. Management reported a soft headline - sales up 7% but roughly 0% organic, EBITA margin around 17%, and Specialty Pharma's result down more than 50% on the UK melatonin loss. Crucially, they did not hide it. They named the melatonin royalty decline specifically, quantified it, and set out the fix: broaden Unimedic's portfolio through more licensing and acquisitions, while warning that this would mean higher near-term regulatory and launch-preparation costs. That is a specific, falsifiable promise.

By Q2 2025 they delivered on the operational promise: the quarter was described as the strongest EBITA to date, up around 20% adjusted for acquisition costs, and the promised Specialty Pharma portfolio-broadening arrived concretely with the XGX Pharma agreement. The commitment made in Q1 ("we will broaden the portfolio through acquisition") was met within one quarter.

Q3 2025 showed the pattern holding: Group EBITA up 12% reported and 32% adjusted, XGX closed on 21 July as promised, and management was again honest that the CDMO was "slightly weaker than last year" and undergoing improvement measures. They flagged, rather than buried, the CDMO softness - the same candour as Q1.

Q4/FY 2025 (Jan 2026) closed the year with net sales up 17% and adjusted EBITA up 26%, attributing the growth to the Danrehab, XGX, and LivAssured acquisitions plus organic growth in Assistive Tech and MedTech. They repeated that Specialty Pharma had fallen more than 50% on the UK change - consistent messaging with Q1, no revisionism. Every acquisition promised or announced during the year had closed.

Q1 2026 (Apr 2026) is where the guidance turned forward: sales up 13% to SEK 556.6m, adjusted EBITA up 30% to SEK 109.6m, margin recovering to 19.7%, balance sheet at ~0.2x net debt/EBITDA. Management made a specific forward commitment:

Specialty Pharma margin is "expected to improve in the second half of 2026 and beyond."

Q2 2026 (21 Jul 2026) then delivered ahead of that recovery timetable: sales up 16% to SEK 606.3m, EBITA up 38% to SEK 129.5m, margin expanding to 21.4%, and H1 sales up 15% to SEK 1,162.9m with EBITA up 36%. The margin was already climbing before the promised H2 window, and the Biopsafe deal closed on schedule in June. All business areas were reported as contributing.

The trackable record:

The plain assessment: this is a management team that does what it says. It is consistently candid about the weak leg (Specialty Pharma / CDMO), quantifies bad news rather than obscuring it, and reliably closes the acquisitions it announces. It is neither a serial over-promiser nor a sandbagger; the guidance has been accurate and the operational delivery steady. The one honest caveat is that the strongest results (2025-2026 margin expansion) were partly acquisition-driven, so the reader should keep watching organic growth and integration quality rather than headline growth alone.

Section 10: Shareholder friendliness index

Dividends. MedCap has paid no dividend, in the last three years or for many years before that. This is deliberate and consistent with the model: the company reinvests all cash flow into organic growth and bolt-on acquisitions, and it explicitly positions itself as a long-term reinvesting compounder rather than an income stock. There is no payout ratio to discuss because the payout is zero by design. A shareholder buying MedCap is buying reinvestment and compounding, not yield.

Buybacks and dilution. MedCap is not a return-of-capital buyback story either. The one repurchase programme in the recent window was small and mechanical: authorised at the 5 May 2025 AGM and run 8-27 May 2025, it repurchased 58,442 shares for SEK 25,998,155 (about SEK 26m), and its stated purpose was to fund the LTIP 2025/2028 long-term incentive plan, adapt capital structure, and enable share-financed acquisitions - not to shrink the count for shareholders. The MoatMap database confirms zero buybacks in the trailing ~90 days (since 25 April 2026), consistent with the programme having ended in mid-2025. Against a share base of roughly 15 million, that buyback is immaterial, and share-based incentive plans create modest offsetting dilution, so the net count over three years is broadly flat with a slight upward bias from incentive schemes. Cash is being kept on the balance sheet (net debt/EBITDA ~0.2x) explicitly to fund acquisitions.

Verdict: Hoards Capital (in the constructive sense) - MedCap returns essentially nothing to shareholders and reinvests all cash into acquisitions and growth, which is the entire premise of owning it.

Section 11: Insider activities

Source: MoatMap's Nasdaq Stockholm / Finansinspektionen PDMR feed (the block injected above), cross-checked as the spine for the last 12 months. Nasdaq Stockholm insider filings run through the Finansinspektionen insider register (marknadssok.fi.se) under EU MAR Article 19.

The 12-month picture is dominated by selling, but the character of it matters more than the direction.

The buys. There is one genuine open-market purchase in the window: board/management member Anders Larnholt bought 1,500 shares for ~SEK 780,000 on 9 February 2026. But it is offset almost exactly by a same-day 1,500-share sale from his own holding company at a near-identical price - this is a transfer of shares between his personal name and his förvaltnings-bolag (management company), not a fresh conviction bet. Treated properly, there is no meaningful net open-market insider buying in the last 12 months.

The sells - reading the why. The largest activity clusters on 3-4 December 2025 and looks like incentive-plan mechanics rather than a bearish exit. Both CEO Anders Dahlberg and board member Tove Christiansson recorded an "Other" acquisition at exactly SEK 386.75 (a below-market price consistent with an incentive/option strike or LTIP allocation) immediately followed by an open-market "Sell" at the prevailing ~SEK 527 market price. The classic pattern is acquiring shares through the incentive plan and selling a portion to cover the cost or tax. Christiansson's net position still fell (she sold 17,500 against 22,000 acquired, plus three further small February sales), so she did reduce, but the mechanism is incentive-linked, not a signal about the business. Dahlberg's December activity netted to roughly flat (2,000 acquired, 2,000 sold).

Chairman Karl Tobieson sold 3,367 shares (SEK ~1.81m) and 3,000 shares (SEK ~1.60m) on 4-5 December 2025 in plain open-market sales with no offsetting acquisition and no disclosed reason. As the architect of modern MedCap and still a large holder, his ~SEK 3.4m of selling is worth noting but is small relative to his overall stake and is most plausibly personal diversification. Reason not disclosed.

Net assessment. Insiders were net sellers over the last 12 months, but the selling is concentrated in a few people and is overwhelmingly incentive-plan mechanics (acquire-at-strike, sell-to-cover) plus modest founder/chairman diversification, not a broad-based exit. There is no cluster of open-market buying to point to as a bullish signal, and no single dramatic disposal that reads as a red flag. The honest read is neutral with a mild negative tilt: no insider is stepping up to buy shares on the open market at current prices, and the chairman trimmed, but nothing here suggests insiders see the business deteriorating.

Section 12: Scenarios

Bull case. MedCap's compounding flywheel keeps turning and accelerates. Assistive Tech and MedTech continue their steady organic growth while the bolt-on machine keeps finding well-priced Nordic niche leaders, financed from a balance sheet that stays near-unlevered. Biopsafe's biopsy-container consumable scales internationally, Nightwatch rolls out across Abilia's channel, and, most importantly, Specialty Pharma turns from headache to engine: the XGX pipeline of ~20 niche products starts launching, the melatonin/CDMO drag fully annualises out, and the segment's margin recovers as management promised and then keeps climbing. The group's margin, already at 21.4% in Q2 2026, ratchets higher as the mix shifts toward proprietary MedTech consumables and higher-margin specialty medicines. Two or three years out, MedCap looks like a proven mini-Lifco of healthcare - a diversified, defensive, self-funding portfolio of niche leaders compounding steadily, with acquisition optionality still ahead of it and no leg dragging the group.

Base case. Management delivers roughly what it has guided. Assistive Tech and MedTech grow organically in the mid-single-to-low-double digits, supplemented by a steady drumbeat of small acquisitions each year. Specialty Pharma's margin improves through H2 2026 as guided but remains the volatile leg, occasionally surprising in either direction on a single product or CDMO contract. Group revenue and EBITA keep growing at the mid-teens rate seen in 2025-2026, driven by a blend of organic growth and M&A, with margins grinding modestly higher. Nothing breaks; nothing dramatically outperforms. MedCap remains what it is: a disciplined Nordic healthcare compounder that reinvests everything, pays no dividend, and rewards patience rather than delivering fireworks. The main watch-item is whether organic growth stays healthy underneath the acquisition-driven headline.

Bear case. The concentration risks inside Specialty Pharma bite again. A second niche product or royalty stream suffers a UK-melatonin-style regulatory or reimbursement shock, and the CDMO loses another chunk of external volume, so the segment's recovery stalls or reverses instead of improving as promised. Simultaneously, the acquisition engine misfires: with more capital to deploy each year, MedCap overpays for a bolt-on, the XGX earn-out crystallises without the expected gross-profit growth, or an integration disappoints, and the market realises the group's headline growth was leaning on M&A while organic growth was quietly soft. Nordic public-budget austerity or a re-tender loss pressures Assistive Tech pricing at the same time. Margins stall, the compounding narrative loses its shine, and with no dividend and no buyback to cushion sentiment, the shares are left to reflect a slower, more ordinary niche-holding company than the market had come to expect. None of these is catastrophic on its own; the bear case is that two or three arrive together and the reinvestment story stops looking like compounding.